US 10,376,536 B2
Multiple sclerosis treatment
Stephen Donald Wilton, Applecross (AU); Sue Fletcher, Bayswater (AU); and May Aung-Htut, Willetton (AU)
Assigned to MURDOCH UNIVERSITY, Murdoch (AU)
Appl. No. 15/573,184
Filed by MURDOCH UNIVERSITY, Murdoch (AU)
PCT Filed May 10, 2016, PCT No. PCT/AU2016/000158
§ 371(c)(1), (2) Date Nov. 10, 2017,
PCT Pub. No. WO2016/179634, PCT Pub. Date Nov. 17, 2016.
Claims priority of application No. 2015901703 (AU), filed on May 11, 2015.
Prior Publication US 2018/0104273 A1, Apr. 19, 2018
Int. Cl. C12N 15/11 (2006.01); C12N 15/113 (2010.01); A61K 31/7105 (2006.01); A61K 48/00 (2006.01)
CPC A61K 31/7105 (2013.01) [A61K 48/005 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12N 2310/11 (2013.01); C12N 2320/33 (2013.01)] 14 Claims
 
1. An integrin alpha-4 (ITGA4) antisense oligomer comprising at least 95% sequence identity to the nucleotide sequence of SEQ ID NO: 21 or 131, wherein the antisense oligomer comprises a modified backbone structure or a modified sugar moiety.